z-logo
Premium
Megakaryocytes in myelodysplasia: an immunohistochemical study on bone marrow trephines
Author(s) -
FOX S.B.,
LORENZEN J.,
HERYET A.,
JONES M.,
GATTER K.C.,
MASON D.Y.
Publication year - 1990
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.1990.tb00665.x
Subject(s) - trephine , megakaryocyte , pathology , bone marrow , immunohistochemistry , staining , myelodysplastic syndromes , monoclonal antibody , myeloproliferative disorders , medicine , hematopathology , haematopoiesis , biology , antibody , immunology , cytogenetics , stem cell , genetics , biochemistry , gene , chromosome
Megakaryocytes in 63 bone marrow trephine biopsies were examined for their staining characteristics, location and size distribution using the monoclonal antibody Y2/51 directed against platelet glycoprotein IIIa (CD61). Megakaryocytes in normal bone marrow were evenly distributed and demonstrated homogeneous staining with Y2/51. In addition, there was little variation in their size or shape. In contrast, myelodysplastic and myeloproliferative bone marrow trephines showed considerable dysmegakaryopoiesis demonstrated by heterogeneity of staining, an altered architectural distribution with a predominantly paratrabecular location and considerable variation in size and shape. Furthermore, in myelodysplasia 25% of the CD61 positive cells were micromegakaryocytes as opposed to less than 10% in normal or reactive marrows. Such dysmegakaryopoiesis is believed to be a clinically important feature of myelodysplasia, although until now it has only been possible to assess it subjectively. The availability of the monoclonal antibody Y2/51 provides a rapid and reproducible means of studying megakaryocyte size, shape and distribution in routine trephine specimens and may help to overcome some of the diagnostic problems currently associated with myelodysplasia and other intrinsic bone marrow neoplasias.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here